We observed that paclitaxel (20 nM), a first-line breast cancer chemotherapy, increased eIF2α phosphorylation, while reducing phospho-4E-BP1 levels in T47D and SUM149 cells (Fig. 6a; Supplementary Fig. 6a). This evidence concerns the gene EIF4EBP1 and breast cancer.